Linda R. Duska

Obstetrics and Gynecology

1221 Lee St Fl 3
Charlottesville, VA 22903

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Update on immune checkpoint inhibition for cervical cancer.

Update on immune checkpoint inhibition for cervical cancer.

Journal: Clinical advances in hematology & oncology : H&O

Published: May 07, 2026

MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.

MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.

Journal: Gynecologic oncology

Published: February 15, 2026

Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III-IVA cervical cancer in the United States.

Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III-IVA cervical cancer in the United States.

Journal: Gynecologic oncology

Published: January 20, 2026

Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype.

Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype.

Journal: Gynecologic oncology

Published: December 12, 2025

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

Journal: Gynecologic oncology

Published: December 07, 2025

Correction: Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer.

Correction: Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer.

Journal: Oncology and therapy

Published: September 04, 2025

Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types.

Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types.

Journal: Journal of the National Cancer Institute

Published: August 13, 2025

Opportunistic Salpingectomy.

Opportunistic Salpingectomy.

Journal: JAMA surgery

Published: August 13, 2025

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.

Journal: The oncologist

Published: April 29, 2025

Dostarlimab and niraparib in primary advanced ovarian cancer.

Dostarlimab and niraparib in primary advanced ovarian cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 11, 2025

Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer.

Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer.

Journal: Oncology and therapy

Published: April 07, 2025

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

Journal: Cancer

Published: December 27, 2024

Showing 1-12 of 135

Last Updated: 09/26/2026